ERBB2 and ovarian mucinous adenocarcinoma: Ultimately, this case highlights the ongoing need for further prospective evaluation of targeted therapeutics in mucinous ovarian carcinoma with special attention paid to the identification and treatment of patients with ERBB2-amplified tumors.